Spyre Therapeutics, Inc. (SYRE) Stock Price & Analysis

Spyre Therapeutics, Inc. (SYRE) closed at USD 92.33 on Thursday, October 22, 2026, down 0.67% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 92.95; the Oct 22, 2026 session ranged USD 91.27–94.57 on volume of 802,927 shares. Market capitalization is $8.63B, with a 52-week range of USD 21.15–110.18 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:48 UTC.

Also available as compact Markdown for AI agents: nexqual.com/SYRE.md

Key facts (SYRE)

• Insider open-market sales, last ~7 months: 22 Form 4 filings, $438M; 2 not under a Rule 10b5-1 plan ($401M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.00 on a 1–5 scale) (18 analysts), mean target USD 122.33 (range 110–130).
• Total return with dividends: 1Y +312.7% vs S&P 500 +14.9%; 5Y -49.4% vs S&P 500 +80.3%.
• Next earnings: 2026-11-03, EPS estimate USD -0.84, revenue estimate $0K.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SYRE)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (SYRE)

P/B 7.8x · Earnings yield -2.07%

Insider sales (SEC Form 4, open-market, last ~7 months) (SYRE)

20 of 22 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (SYRE)

Consensus Buy (mean 2.00 on a 1–5 scale), 18 analysts; mean target USD 122.33 (low 110, high 130).

Rating changes, last 120 days:

Total return (dividends reinvested) (SYRE)

SYRE suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 19, 2026.

SYRE company outlook (results filed Aug 4, 2026)

• “Enrollment for Part A has completed, with SPY001 and SPY002 Part A topline induction data announced in Q2 2026, and topline data expected for SPY003 in September 2026. ◦ Topline induction data from Part A of the SKYLINE trial in UC subjects were presented in April 2026 and June 2026 for SPY001 and SPY002, respectively.”
• “Topline proof-of-concept data are expected in September 2026. • PsA sub-study: Double-blind, placebo-controlled safety and efficacy study of a single dose level of SPY072 at Week 16 with open-label follow-up through Week 40.”
• “Topline proof-of-concept data are expected in the fourth quarter of 2026. • axSpA sub-study: Double-blind, placebo-controlled safety and efficacy study of a single dose level of SPY072 at Week 16 with open-label follow-up through Week 40.”
• “Topline proof-of-concept data are expected in the fourth quarter of 2026.”

Quoted word-for-word from the SEC 8-K results press release.

SYRE analyst estimates and revisions

SYRE options: expected move

Options price a move of about ±17.7% (±$16.30) by Nov 20, 2026, which includes earnings on Nov 3, 2026. Over the last 8 reports the stock moved ±11.5% on average.

30-day implied volatility 75.4% vs 65.4% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 09:48 UTC)

Technical Analysis (SYRE)

Nexqual's technical model rates SYRE "BUY" based on 4 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:48 UTC.

Analyst Ratings (SYRE)

Wall Street analysts rate SYRE "Buy" based on 18 analysts, with a mean price target of USD 122.33 (range USD 110–130), per Nexqual as of October 23, 2026 at 09:48 UTC.

Earnings (SYRE)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 09:48 UTC.

Financials & Fundamentals (SYRE)

Source: Nexqual, October 23, 2026 at 09:48 UTC.

Financial Health Score (SYRE)

Nexqual rates Spyre Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 09:48 UTC.

Ownership (SYRE)

Source: Nexqual, October 23, 2026 at 09:48 UTC.

Leadership (SYRE)

Spyre Therapeutics, Inc. is led by Cameron Turtle DPHIL, CEO & Director, per Nexqual as of October 23, 2026 at 09:48 UTC.

Major Backers & Investors (SYRE)

Notable institutional backers of Spyre Therapeutics, Inc. include FMR, LLC, Fidelity, Perceptive Advisors Llc, according to Nexqual as of October 23, 2026 at 09:48 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 09:48 UTC.

From Spyre Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)

Key Strengths & Strategy (as disclosed to the SEC)

• We seek to protect our proprietary information, in part by executing confidentiality agreements with our collaborators and scientific advisors, and non-competition, non-solicitation, confidentiality and invention assignment agreements with our employees and consultants.
• The confidentiality agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies that are developed through our relationship with the respective counterparty.
• Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the full commercial value of our product candidates.
• Our manufacturing strategy enables us to more efficiently direct financial resources to the research, development and commercialization of programs rather than diverting resources to internally develop and maintain manufacturing facilities.

Partnerships

• With respect to the SPY002 License Agreement only, on a product by product basis, we are obligated to pay sublicensing fees of up to approximately $20 million upon the achievement of mostly commercial milestones.
• In May 2023, Pre-Merger Spyre entered into the Paragon Agreement with Paragon and Parapyre.

Legal & Regulatory Risks (Item 1A, quoted)

• We may not be able to achieve our timelines or obtain timely regulatory approvals of product candidates.
• We may not be able to meet requirements for chemistry, manufacturing and control of our programs.
• Our product candidates may face competition sooner than anticipated based on rules and regulations that may apply or government decisions with respect to our intellectual property.
• We may be negatively impacted by healthcare legislative reform measures and other changes in law.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:48 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt